<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124160</url>
  </required_header>
  <id_info>
    <org_study_id>CCN016</org_study_id>
    <nct_id>NCT03124160</nct_id>
  </id_info>
  <brief_title>Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard</brief_title>
  <official_title>A Multi-center, Single-blind, Randomized Clinical Trial to Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Decisions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-site, participant-blinded, randomized clinical trial. The investigators&#xD;
      will randomize 1000 eligible participants in a 4:1 ratio to two different copper IUDs: 800 to&#xD;
      Mona Lisa NT Cu380 Mini and 200 to ParaGard.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study for each participant is expected to be approximately 39&#xD;
      months: including screening and enrollment (up to 30 days to meet enrollment criteria), 37&#xD;
      months of participation, and a post-removal follow up telephone call 17 days post-removal.&#xD;
      After enrollment, subject visits occur at 6 weeks, 3 months, 6 months, 12 months, 24 months,&#xD;
      with telephone calls at 9, 18, and 30 months and seen again at 37 months for their final&#xD;
      visit. Subjects will use a home pregnancy test 17 days post-removal of the IUD or Exit Visit&#xD;
      procedures, whichever occurs first, and called by the site for the result and for safety&#xD;
      follow-up.&#xD;
&#xD;
      Subject recruitment is expected to begin Q2 (in the second quarter of) 2017 and is planned to&#xD;
      continue through Q2 2018. However, if the enrollment rate declines, the enrollment period may&#xD;
      be extended beyond this date. If this enrollment timeline is met, all subjects should finish&#xD;
      active treatment by approximately the end of Q2 2021. The total duration of the study will be&#xD;
      approximately 48 months for each study site including pre- and post- trial activities. The&#xD;
      end of the study will occur when the last subject to be enrolled has completed her&#xD;
      post-removal pregnancy test telephone call.&#xD;
&#xD;
      Total duration of the project is expected to be five years. Preliminary results of the study&#xD;
      are expected to be available Q4 of 2019 based on the current study plan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 26, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IUD continuation at months 12, 24 and 36 as measured by confirmation of IUD placement (visible or palpable)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failed IUD insertion as measured by inability to place the IUD correctly</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine perforation as measured by ultrasound</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IUD expulsion (complete and partial)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal bleeding patterns</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic pain as measured in the subject diary</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other side effects as measured by adverse and/or other events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with and shortly after insertion as measured by visual analog scale completed by study subjects</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of IUD insertion as measured by asking the investigator to assess ease of insertion</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall product satisfaction as measured by acceptability questions asked of subjects</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Healthy Women</condition>
  <condition>Female Contraception</condition>
  <arm_group>
    <arm_group_label>Mona Lisa® NT Cu380 Mini</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ParaGard® CuT380A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mona Lisa® NT Cu380 Mini</intervention_name>
    <description>Mona Lisa® NT Cu380 Mini</description>
    <arm_group_label>Mona Lisa® NT Cu380 Mini</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ParaGard® CuT380A</intervention_name>
    <description>ParaGard® CuT380A</description>
    <arm_group_label>ParaGard® CuT380A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  16-40 years&#xD;
&#xD;
             o 16 and 17 year olds, where permissible by state regulations and local Institutional&#xD;
             Review Board (IRB) approval&#xD;
&#xD;
          -  Sexually active, anticipating at least one act of vaginal intercourse per menstrual&#xD;
             cycle with a male partner and at risk for pregnancy&#xD;
&#xD;
          -  seeking contraception, and willing to use the study IUD as the only contraception&#xD;
             method&#xD;
&#xD;
          -  willing to be randomized to one of the two copper IUDs&#xD;
&#xD;
          -  has an intact uterus and at least one ovary&#xD;
&#xD;
          -  has a history of regular menstrual cycles; defined as occurring every 21-35 days when&#xD;
             not using hormones, and with a variation of typical cycle length of no more than 5&#xD;
             days&#xD;
&#xD;
          -  able and willing to provide written informed consent&#xD;
&#xD;
          -  agrees to follow all study requirements&#xD;
&#xD;
          -  not currently pregnant or at risk for luteal phase pregnancy based on history of&#xD;
             unprotected intercourse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormal Pap requiring treatment after enrollment&#xD;
&#xD;
          -  known human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS)&#xD;
             infection&#xD;
&#xD;
          -  intending to become pregnant in the 37 months after enrollment&#xD;
&#xD;
          -  known infertility&#xD;
&#xD;
          -  history of allergy or sensitivity to copper&#xD;
&#xD;
          -  previous tubal sterilization&#xD;
&#xD;
          -  has received an injectable contraceptive in the last 9 months and has not resumed&#xD;
             regular menstrual cycles (as evidenced by 2 spontaneous menses)&#xD;
&#xD;
          -  within 30 days of administration of mifepristone and/or misoprostol for medical&#xD;
             abortion or for miscarriage management&#xD;
&#xD;
          -  within 30 days of first, second, or third trimester abortion or miscarriage (note:&#xD;
             potential abortion/miscarriage participants can be screened and return after 30 days&#xD;
             for randomization and IUD insertion)&#xD;
&#xD;
          -  within 30 days of delivery (for parous population)&#xD;
&#xD;
          -  breastfeeding or recently breastfeeding women unless two consecutive normal menstrual&#xD;
             periods have occurred after delivery and prior to enrollment.&#xD;
&#xD;
          -  wants to use a copper IUD for emergency contraception&#xD;
&#xD;
          -  has previously participated in the study&#xD;
&#xD;
          -  participated in another clinical trial involving an investigational product within the&#xD;
             last 30 days (before screening) or planning to participate in another clinical trial&#xD;
             involving an intervention or treatment during this study&#xD;
&#xD;
          -  not living in the catchment area of the study site or planning to move from the area&#xD;
             within the year (unless known to be moving to the catchment area of another study&#xD;
             site)&#xD;
&#xD;
          -  known or suspected current alcohol or drug abuse&#xD;
&#xD;
          -  planning to undergo major surgery during study participation&#xD;
&#xD;
          -  current need for use of exogenous hormones or therapeutic anticoagulants (Note:&#xD;
             subjects who start a therapeutic anticoagulant after enrolment will be allowed to&#xD;
             continue in the study.)&#xD;
&#xD;
          -  at high risk for sexually-transmitted infections or pelvic infection&#xD;
&#xD;
          -  anticipated need for regular condom use (refer to Section 8.1).&#xD;
&#xD;
          -  has any condition (social or medical) which in the opinion of the Investigator would&#xD;
             make study participation unsafe or complicate data interpretation&#xD;
&#xD;
          -  Reported medical contraindications (Medical Eligibility Criteria category 3 or 4)14 to&#xD;
             copper IUDs, including:&#xD;
&#xD;
               -  suspicious unexplained vaginal bleeding&#xD;
&#xD;
               -  known cervical cancer&#xD;
&#xD;
               -  known endometrial cancer&#xD;
&#xD;
               -  known Wilson's disease&#xD;
&#xD;
               -  Confirmed gestational trophoblastic disease with persistently elevated beta-hCG&#xD;
                  levels or malignant disease, with evidence or suspicion of intrauterine disease&#xD;
&#xD;
               -  anatomic abnormalities with distorted uterine cavity&#xD;
&#xD;
               -  current pelvic inflammatory disease (PID)&#xD;
&#xD;
               -  pelvic tuberculosis&#xD;
&#xD;
               -  immediately post-septic abortion or puerperal sepsis&#xD;
&#xD;
               -  current known purulent cervicitis or chlamydial infection or gonorrhea; Note: to&#xD;
                  enroll, there must be no obvious signs of infection at the time of enrollment&#xD;
                  based on pelvic exam. If lab results come back for positive infection after&#xD;
                  enrollment, treatment should be provided but the IUD can be left in place.&#xD;
&#xD;
               -  complicated solid organ transplantation&#xD;
&#xD;
               -  systemic lupus erythematosus with severe thrombocytopenia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Blithe</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Child Health &amp; Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hubacher</last_name>
    <role>Study Director</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Essential Access Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Corporation</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood League of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018680s066lbl.pdf</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of U.S. experience, 1970-75. Stud Fam Plann. 1979 Oct;10(10):263-81.</citation>
    <PMID>516121</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Tatum HJ. Four years of experience with the TCu 380A intrauterine contraceptive device. Fertil Steril. 1981 Aug;36(2):159-63.</citation>
    <PMID>7262334</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Stern J, Coutinho E, Mattos CE, el Mahgoub S, Diaz S, Pavez M, Alvarez F, Brache V, Thevenin F, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991 Nov;44(5):473-80.</citation>
    <PMID>1797462</PMID>
  </reference>
  <reference>
    <citation>The TCu380A, TCu220C, multiload 250 and Nova T IUDS at 3,5 and 7 years of use--results from three randomized multicentre trials. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on the Safety and Efficacy of Fertility Regulating Methods. Contraception. 1990 Aug;42(2):141-58.</citation>
    <PMID>2085966</PMID>
  </reference>
  <reference>
    <citation>Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007 Jun;75(6 Suppl):S8-11. Epub 2007 Feb 20. Review.</citation>
    <PMID>17531622</PMID>
  </reference>
  <reference>
    <citation>Abraham M, Zhao Q, Peipert JF. Young Age, Nulliparity, and Continuation of Long-Acting Reversible Contraceptive Methods. Obstet Gynecol. 2015 Oct;126(4):823-829. doi: 10.1097/AOG.0000000000001036.</citation>
    <PMID>26348177</PMID>
  </reference>
  <reference>
    <citation>Benacerraf BR, Shipp TD, Lyons JG, Bromley B. Width of the normal uterine cavity in premenopausal women and effect of parity. Obstet Gynecol. 2010 Aug;116(2 Pt 1):305-310. doi: 10.1097/AOG.0b013e3181e6cc10.</citation>
    <PMID>20664389</PMID>
  </reference>
  <reference>
    <citation>Koch P, Reinhardt P, Soyka E. Intrauterine contraception using the Copper Mini-Gravigard 7 IUD: summary of 328 case histories. Contracept Deliv Syst. 1981 Apr;2(1):171-6.</citation>
    <PMID>12336868</PMID>
  </reference>
  <reference>
    <citation>Petersen KR, Brooks L, Jacobsen N, Skoby SO. Clinical performance of intrauterine devices in nulligravidae: is the length of the endometrial cavity of significance? Acta Eur Fertil. 1991 Jul-Aug;22(4):225-8.</citation>
    <PMID>1844327</PMID>
  </reference>
  <reference>
    <citation>Otero-Flores JB, Guerrero-Carreño FJ, Vázquez-Estrada LA. A comparative randomized study of three different IUDs in nulliparous Mexican women. Contraception. 2003 Apr;67(4):273-6.</citation>
    <PMID>12684147</PMID>
  </reference>
  <reference>
    <citation>Ott MA, Sucato GS; Committee on Adolescence. Contraception for adolescents. Pediatrics. 2014 Oct;134(4):e1257-81. doi: 10.1542/peds.2014-2300. Review.</citation>
    <PMID>25266435</PMID>
  </reference>
  <reference>
    <citation>Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012 Oct;120(4):983-8.</citation>
    <PMID>22996129</PMID>
  </reference>
  <reference>
    <citation>Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. doi: 10.15585/mmwr.rr6503a1.</citation>
    <PMID>27467196</PMID>
  </reference>
  <reference>
    <citation>Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015 Apr;91(4):274-9. doi: 10.1016/j.contraception.2015.01.007. Epub 2015 Jan 16.</citation>
    <PMID>25601352</PMID>
  </reference>
  <reference>
    <citation>Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992 Mar 28;339(8796):785-8.</citation>
    <PMID>1347812</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Women</keyword>
  <keyword>Female Contraception</keyword>
  <keyword>IUD</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

